MedChemExpress - Model Codrituzumab - 1365267-33-9
Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth[1][2][3][4].MCE products for research use only. We do not sell to patients.
Codrituzumab
MCE China：Codrituzumab
Brand：MedChemExpress (MCE)
Cat. No.HY-P99013
CAS：1365267-33-9
Synonyms：GC33; RO5137382
Purity：95.70%
Storage：Please store the product under the recommended conditions in the Certificate of Analysis.
Shipping：Shipping with dry ice.
Description：Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth.
In Vitro：Codrituzumab (once-weekly for 21 days) combined with PD-L1 mAb demonstrates a marked antitumor effect, enhancing tumor infiltration of PD-L1-positive immune cells, such as macrophages and multinucleated giant cells in the Hepa1-6/hGPC3 mice model[1].
Species：Humanized
Isotype：Human IgG1 kappa
Recommend Isotype Controls：Human IgG1 kappa, Isotype Control
Hot selling product：SD-36 | Zolbetuximab | Vorinostat | FITC | CORM-401 | Exendin-4 | Procyanidin C1 | MKC8866 | Abemaciclib | Metformin (hydrochloride)
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References：
[2]. Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2;9(12):10436-10444. [Content Brief]
[3]. Carrasquillo JA, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018 Mar 5;8(1):20. [Content Brief]
[4]. Abou-Alfa GK, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):289-95. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
• It has a professional experimental center and strict quality control and verification system；
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
• The biological activity of the products has been verified by the experiments of customers in various countries；
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。